Professional Services Automation by IBN Technologies Accelerates Business Advancement Across U.S. Industries
"Professional Services Automation (USA)"
Professional Services Automation provides USA organizations with instant project visibility and data-driven insights that enhance operational decisions. With IBN Technologies' solutions, companies experience faster response times, improved workflow coordination, and better financial control—key drivers of competitive advantage.
MIAMI, Florida - May 20, 2025 - Business areas throughout the United States are experiencing a significant transformation with the rise of project-centric business models. As professional services continue to evolve, industries are managing an increasing volume of client-focused projects, each with distinct timelines, deliverables, and resource requirements. In this growing environment of complexity and speed, Professional Services Automation provides the operational structure needed for seamless coordination, real-time tracking, and consistent execution.
Companies managing billable work, task allocation, and resource planning are embracing AI and automation, advanced business automation solutions, and intelligent workflow and automation tools. These technologies bring greater visibility, precision, and efficiency to every stage of service delivery. As business operations become more data-driven and collaborative, the adoption of automation signals a clear movement toward smarter, faster, and more scalable professional service models.
Organizations seeking to optimize this evolution are increasingly turning to established service providers. Companies like IBN Technologies bring specialized expertise in implementing Professional Services Automation systems, serving strategic guidance and hands-on support customized to dynamic service environments.
Power business decisions through automation.
Get a Free Consultation: https://www.ibntech.com/free-consultation-for-ipa/
Rethink where Manual Project Management Fails
Managing professional services without automation has become increasingly unsustainable for U.S. businesses. As operations grow more complex, manual methods expose organizations to delays, inefficiencies, and inconsistent results.
Limited real-time visibility into project progress and team output
Delays in client billing due to manual time and expense tracking
Inaccurate forecasting of resource availability and project margins
Disconnected communication across departments and teams
Low staff utilization due to inefficient task scheduling
Difficulty scaling operations while maintaining service quality
Slower decision-making due to lack of centralized performance data
Higher risk of missed deadlines and budget overruns
Many businesses have already resolved these concerns by adopting a structured business process automation workflow and implementing a clear business process automation strategy. Companies like IBN Technologies play a vital role in this shift, helping U.S. organizations streamline operations, align project execution, and maintain high levels of accuracy and efficiency through Professional Services Automation systems.
Automation Supports Scalable Solutions
As USA businesses and industries face growing concerns, many are turning to automation because it provides effective solutions for improving efficiency and accuracy. Automation addresses critical needs in managing finance, sales, medical claims, and payment workflows—helping companies operate faster and smarter.
Robotics Process Automation to eliminate repetitive manual tasks.
AP/AR Automation for faster and error-free accounts payable and receivable management.
Invoice Process Automation to speed up invoice approvals and payments.
Medical Claim Automation ensuring accurate and compliant claim processing.
Sales Order Processing automation to improve order accuracy and fulfillment.
Electronic Funds Transfer for secure and efficient payment transactions.
Invoice Action to streamline accounts payable workflows and reduce processing time.
Order Action to optimize sales and purchase order workflows.
Claim Action to simplify medical claim handling and speed reimbursements.
Remittance Action leveraging AI and OCR to reduce manual effort in remittance handling.
Expense Action to automate expense tracking and simplify reimbursements.
All these are professional services expertly provided by IBN Technologies. With a strong track record, they've supported numerous U.S. businesses in successfully using Professional Services Automation for business process automation. This has helped these companies streamline workflows, reduce errors, and boost nationwide operational performance
"Embracing Professional Services Automation accelerates growth by improving accuracy, transparency, and client satisfaction across all service sectors," said Ajay Mehta, CEO at IBN Technologies.
Proven Results of Automation Services in the USA
A leading HVAC manufacturer in the USA transformed their sales order process by implementing intelligent automation with IBN Technologies. Seamless integration with their SAP system delivered significant gains in accuracy, scalability, and operational visibility.
The order entry time was reduced by 66%, dropping from 7 minutes to 2 minutes.
Across U.S. operations, order accuracy improved significantly, lowering processing errors.
Over 80% of orders in the USA are now automated, greatly increasing efficiency.
Full visibility and accountability were established nationwide, with 100% liability tracking.
These results highlight how business process automation services are producing measurable improvements for companies throughout the USA, optimizing workflows and boosting productivity.
Future-Ready Business Automation
Advanced automation solutions combined with expert guidance are essential for U.S. businesses navigating increasing complexity and accelerating market demands. Companies like IBN Technologies deliver Professional Services Automation that to practical business process automation services that enable organizations to manage current operations efficiently while preparing for sustainable growth. With widespread adoption of AI, machine learning, and intelligent workflows, process automation drives business transformation, significantly boosting competitiveness and operational excellence.
IBN Technologies has a strong record of supporting companies to improve accuracy, reduce costs, and increase processing speed through automation solutions. As the business landscape evolves, organizations leveraging these advanced tools are well-positioned to respond swiftly, enhance customer experiences, and achieve lasting success in the digital economy.
Related Services:
Invoice Processing Automation: https://www.ibntech.com/invoice-process-automation/
About IBN Technologies
IBN Technologies LLC, an outsourcing specialist with 25 years of experience, serves clients across the United States, United Kingdom, Middle East, and India. Renowned for its expertise in RPA, Intelligent process automation includes AP Automation services like P2P, Q2C, and Record-to-Report. IBN Technologies provides solutions compliant with ISO 9001:2015, 27001:2022, CMMI-5, and GDPR standards. The company has established itself as a leading provider of IT, KPO, and BPO outsourcing services in finance and accounting, including CPAs, hedge funds, alternative investments, banking, travel, human resources, and retail industries. It offers customized solutions that drive AR efficiency and growth.
Media Contact
Company Name: IBN Technologies LLC
Contact Person: Pradip
Email: Send Email
Phone: +1 844-644-8440
Address: 66, West Flagler Street Suite 900
City: Miami
State: Florida 33130
Country: United States
Website: https://www.ibntech.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
20 minutes ago
- National Post
Samsara Announces 2025 North America Customer Advisory Board to Accelerate AI-Powered Safety and Efficiency Breakthroughs
Article content Members play a pivotal role in shaping Samsara solutions; meeting to be held today at the premier event for physical operations, Samsara Beyond Article content SAN DIEGO — Samsara Inc. ('Samsara') (NYSE: IOT), the pioneer of the Connected Operations ® Platform, today announced its 2025 North America Customer Advisory Board. Its members are at the forefront of the world's most complex operations, managing vast frontline workforces and asset portfolios, and are responsible for significant economic value. Recognizing the transformative impact of Samsara's AI-powered platform, these leaders have joined forces to help shape Samsara's product roadmap and to exchange insights for safer, more efficient, and sustainable operations for all. Article content 'I've seen firsthand the impact Samsara's platform has made on the industry, and I'm excited to play a role in what's to come,' said Jeff Wright, Vice President of Transportation at Quikrete. 'At Quikrete, we manage complex operations that greatly benefit from Samsara's real-time data. With AI's potential only growing in operations, this is an important moment to partner and drive innovation.' Article content The distinguished members of Samsara's 2025 North America Customer Advisory Board include leaders from organizations such as: Article content ArcBest, Don Davis, Vice President, Fleet Services Artera, Adam Lanier, Chief Safety Officer AWP Safety, Jarrod Wachter, Chief Operating Officer BNSF Railway, Matthew Igoe, Executive Vice President, Operations DHL Express, Fred Matthews, Senior Project Manager, Safety Programs DHL Supply Chain, Jennifer Miller, Vice President, Integrated Transportation Estes, Todd Florence, Chief Information Officer Ferrellgas, Tamria Zertuche, President and Chief Executive Officer First Student, Sean McCormack, Chief Information Officer Frontier Communications, Doug Spurlin, Senior Director, Operations Liberty Energy, Michael Tuomi, Director, HSE and Training MacAllister, Bill Dollard, Director, Corporate Fleet Martin Marietta, Greg Lahrman, Vice President, Enterprise Excellence Maxim Crane Works, Dennis Collins, Vice President, Operations Mohawk Industries, Andy Yearout, Senior Vice President, Supply Chain NiSource, Bill Jefferson, Chief Operations Officer Nutrien Ag Solutions, Adam Lorenz, Senior Director, Fleet and Procurement Operations Performance Food Group, Thomas Olitsky, Vice President, Safety Pike, James Banner, Senior Vice President, Administration and Safety Primoris, Eric Amlee, Vice President, Fleet Operations PS Logistics, Mauricio Paredes, Vice President, Technology Quikrete, Jeff Wright, Vice President, Transportation Republic Services, Brett Rogers, Vice President, Operations Technology Saia, Rohit Lal, Executive Vice President and Chief Information Officer Southeastern Freight Lines, Kerry Stritt, Vice President, Fleet Services Southern California Edison, Karan Kumar, Director, Transportation Services Sysco, Kevin Thomas, Vice President, Global EHSS and Asset Protection Tyson Foods, Phil Vanhook, Managing Director, Transportation Operations UNFI, Tehzin Chadwick, Senior Vice President, Safety UniFirst, Matt Croatti, Senior Vice President, Operations Univar Solutions, Rob McRae, Vice President, Transportation USIC, Tom Karnowski, Vice President, EHS XPO, Greg Pawelski, Vice President, Health and Safety Article content Samsara's platform is advanced by the direct input of its Customer Advisory Board, ensuring its products meet the evolving needs of physical operations. Leaders' insights have shaped innovations like Recognition, a feature that uses AI insights and real-time driver data to identify and celebrate outcomes like safe driving streaks and consistent compliance with regulations. In addition, they've influenced the Asset Tag, a small ruggedized tracker that helps customers find lost or stolen assets, reduce downtime, and streamline inventory management. Article content 'Being on Samsara's Customer Advisory Board has been incredibly valuable because we get to collaborate with other industry leaders and quickly see the results of our product feedback,' said James Banner, Senior Vice President of Administration and Safety at Pike. 'It's a unique opportunity to shape products that transform the way we operate. The Asset Tag is a prime example: we advised on use cases and the product has now reduced theft and improved efficiency for Pike and many others.' Article content Samsara's commitment to building market-leading technology and fostering a collaborative community is foundational to its mission. Its Customer Advisory Board is just one example that demonstrates this, others include Samsara User Groups, Samsara Spark, and Samsara Beyond. Samsara's forums create a space where the industry can connect, share their most pressing challenges, exchange ideas, and spark innovation. These moments drive real-world outcomes and operational excellence. Another popular program, Samsara Professional Credentials, celebrates the expertise of individuals who complete tailored learning experiences through the Samsara Academy. Samsara is proud to help the industry solve complex challenges with technology and community. Article content 'With all the changes AI is bringing to physical operations, the partnership between industry leaders and technology innovators has never been more important,' said Kiren Sekar, Chief Product Officer at Samsara. 'Our advisory board isn't just about adapting to change, but actively shaping the future of this industry and making a lasting impact, together.' Article content Samsara (NYSE: IOT) is the pioneer of the Connected Operations ® Platform, which enables organizations that depend on physical operations to harness Internet of Things (IoT) data to develop actionable insights and improve their operations. With tens of thousands of customers across North America and Europe, Samsara is a proud technology partner to the people who keep our global economy running, including the world's leading organizations across construction, transportation and warehousing, field services, manufacturing, retail, logistics, and the public sector. The company's mission is to increase the safety, efficiency, and sustainability of the operations that power the global economy. Article content Article content Article content
Globe and Mail
20 minutes ago
- Globe and Mail
Botpress Raises $25M Series B to Scale AI Agent Infrastructure
MONTREAL, June 23, 2025 (GLOBE NEWSWIRE) -- Botpress, a platform for building and deploying AI agents, today announced it has raised $25 million USD in Series B funding. The round was led by FRAMEWORK with participation from Inovia Capital, Deloitte Ventures, HubSpot Ventures, Decibel, and existing investors. The new capital will enable Botpress to accelerate platform development, expand global customer support, and scale the company's engineering and go-to-market teams from its headquarters in Quebec. 'Botpress is a powerful end-to-end agentic AI platform built for production at scale,' said Jim Texier, Partner & CTO at FRAMEWORK. 'In a world moving rapidly toward autonomous, LLM-native systems, Botpress empowers builders to create, deploy and monitor intelligent agents and conversational AI. I believe this is the future of Human-AI and AI-AI interactions — and Botpress is leading it.' Solving AI Agent Infrastructure Botpress was founded to address the infrastructure challenges that prevent most companies from moving AI agents into production. While large language models have unlocked new capabilities in reasoning and language understanding, deploying reliable agents still requires significant supporting infrastructure. 'AI agents will replace entire categories of software over the next decade, but most of the infrastructure required to run these agents safely at scale is still missing,' said founder and CEO Sylvain Perron. 'We've spent the last several years building that missing infrastructure layer so companies can run real agents in production today, not just prototypes.' 'Deloitte Ventures was impressed with the Botpress team's agility to deliver an automation offering that unlocks the power of AI through customizable agentic workflows,' says Jon Wolkin, Managing Director at Deloitte Ventures. 'Our investment in this technology aligns with Deloitte's focus and capabilities in servicing clients' emerging needs to scale quickly with agentic AI solutions.' Rapid Growth Driven by Production Deployments Since launching its cloud platform in 2023, Botpress has seen strong growth in both customer adoption and production deployments. The company's revenue has grown significantly over multiple consecutive quarters, with thousands of customers now running live agents across industries including customer support, fintech, IT services, consumer technology, and more. "We're excited about how Botpress helps businesses move from experimenting with AI agents to actually deploying them," said Adam Coccari, Managing Director at HubSpot Ventures. "Many companies can build agent prototypes, but getting them to work reliably with existing business systems is where most efforts stall. Botpress has built the infrastructure and connections that bridge this gap, and their integration with HubSpot enables our customers to deploy agents that easily connect with their CRM and existing workflows." About Botpress Botpress is a platform for building and deploying AI agents. Founded in Quebec, Canada, Botpress provides the infrastructure layer that allows companies to deploy autonomous agents safely, reliably, and at scale. Start building today at A photo accompanying this announcement is available at
Globe and Mail
20 minutes ago
- Globe and Mail
Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer
NEEDHAM, Mass., June 23, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced the appointment of Charles Schoch as Chief Financial Officer (CFO). Mr. Schoch, who has served as interim CFO of Candel since January 2024, will transition to the CFO role permanently, effective immediately. 'Charles has demonstrated exceptional financial and organizational leadership during his tenure as interim CFO,' said Paul Peter Tak, M.D., Ph.D., FMedSci, President and Chief Executive Officer of Candel. 'He has effectively supported our strategic priorities in a complex market environment while maintaining disciplined capital management. His deep understanding of our business will continue to be instrumental as we advance our clinical pipeline, prepare for our Biologics License Application submission for CAN-2409 in localized prostate cancer, and execute on our near- and long-term corporate goals.' Since joining Candel in November 2021, Mr. Schoch has served in various financial reporting and accounting positions of increasing responsibility, most recently as VP of Finance and Corporate Controller, before being named interim CFO in January 2024. In his interim CFO role, Mr. Schoch developed significant investment banking relationships and has led the company through engagements with top-tier institutional investors, culminating in a previously-announced capital raise with net proceeds of approximately $86 million following the disclosure of positive results in the phase 3 clinical trial of CAN-2409 in localized prostate cancer in December 2024. In January 2025, he was promoted to Senior VP. During his time at Candel, Mr. Schoch has built a high-performing finance function that oversees Candel's financial close process, internal controls, SEC reporting, financial planning, procurement, payroll, and treasury operations. Mr. Schoch has also worked closely with Candel's executive leadership team on investor relations, business development, and financing initiatives. Prior to joining Candel, Mr. Schoch served as Corporate Controller at Corbus Pharmaceuticals from 2019 to 2021. Before Corbus, he spent seven years in PwC's Health Industry assurance practice where he served a diverse group of audit clients, ranging from pre-IPO to multinational public companies within the life sciences sector. Earlier in his career, Mr. Schoch worked for several Third Rock Venture portfolio companies as a financial and operational consultant. Mr. Schoch holds an M.B.A. and M.S.A. from Northeastern University and a B.S. in business administration with a concentration in finance from Elon University. 'I am honored to continue serving in this role and excited about the opportunities that lie ahead for Candel,' commented Mr. Schoch. 'Our strong financial foundation and disciplined approach to capital allocation and value creation position us well for sustainable growth. As we advance our promising clinical pipeline and prepare for key milestones, my focus remains on maintaining financial stability while strategically investing in our future. I look forward to working with our talented team on our goals of driving value for our stakeholders and ultimately helping to deliver clinically meaningful solutions to cancer patients in need.' About Candel Therapeutics Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of CAN-2409 in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal phase 3 clinical trial of CAN-2409 in localized prostate cancer, conducted under a Special Protocol Assessment (SPA) agreed with the U.S. Food and Drug Administration (FDA). CAN-2409 plus prodrug (valacyclovir) has been granted Fast Track Designation by the FDA for the treatment of PDAC, stage III/IV NSCLC in patients who are resistant to first line PD-(L)1 inhibitor therapy and who do not have activating molecular driver mutations or have progressed on directed molecular therapy and localized primary prostate cancer. The FDA most recently also granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CAN-2409 for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease and Orphan Drug Designation to CAN-2409 for the treatment of PDAC. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma (rHGG). Initial results were published in Nature and CAN-3110 received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs, expectations regarding the submission of the BLA for CAN-2409 in intermediate-to-high-risk localized prostate cancer; and expectations regarding the therapeutic benefit of the Company's platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult to treat, solid tumors. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Investor Contact: Theodore Jenkins VP, Investor Relations and Business Development Candel Therapeutics, Inc. tjenkins@
